Compare AADX & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AADX | ZLAB |
|---|---|---|
| Founded | N/A | 2013 |
| Country | | China |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | 2026 | 2017 |
| Metric | AADX | ZLAB |
|---|---|---|
| Price | $17.99 | $25.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.60 |
| AVG Volume (30 Days) | ★ 1.1M | 983.0K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $16.57 | $15.96 |
| 52 Week High | $24.24 | $35.45 |
| Indicator | AADX | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 73.93 |
| Support Level | $16.74 | $16.98 |
| Resistance Level | $19.50 | $26.66 |
| Average True Range (ATR) | 1.36 | 1.18 |
| MACD | -0.22 | 0.57 |
| Stochastic Oscillator | 11.68 | 87.07 |
Applied Aerospace & Defense Inc specializes in providing engineering and vertically integrated manufacturing solutions for space and defense technology companies. The company builds complex hardware for extreme operating environments, combining deep material science and IP-enabled process expertise with the ability to enable rapid prototyping, enhance new product development, and responsively scale production. The majority of the company's revenue is derived from the sales of Defense Aviation and Airborne Systems, followed by Space and Launch Systems, C5ISR and Precision Strike Systems.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.